Observing Blood Clots in the Heart in Patients With Atrial Fibrillation
Studies how clots in the heart respond to blood thinners in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)
Key facts
- Where
- Xi'an, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with atrial fibrillation and a blood clot in the heart, confirmed by an ultrasound through the food pipe, who have not yet had blood-thinning treatment.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Atrial fibrillation found on a 12-lead ECG or Holter, with a heart clot confirmed by transesophageal echocardiography.
- Earlier treatment
- Must not have had any anticoagulant (blood-thinning) treatment.
Main reasons for not taking part
- Heart valve disease confirmed by echocardiography
- Cannot take anticoagulants
- Previous stroke caused by bleeding
- Bleeding or clotting disorders, or low or poorly working platelets
- Kidney failure (creatinine clearance under 30 ml/min) or liver enzymes more than 2 times the upper limit
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06141538, who can take part
Where in China
- First Affiliated Hospital of Xian Jiantong UniversityXi'an, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital Xi'an Jiaotong University
- Trial code
- NCT06141538
- Record updated
- 4 April 2024
- Original description
This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.Read full original descriptionShow less
Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Observational Cohort Study
This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.
Inclusion: Age ≥18 years old, age ≤80 years old; Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter; Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy.
Exclusion: Patients with the previous history of hemorrhagic stroke; Surgery was planned within the intended study time or had been operated within 30 days before the study; Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators; Echocardiography confirmed valvular heart disease; Congenital or acquired coagulation or bleeding disorders; Other comorbidities that can cause bleeding, such as tumors; Low platelet count or functional platelet defects; Renal failure (endogenous creatinine clearance <30ml/min); Contraindications to anticoagulants; Abnormal liver function (liver enzymes >2 times the upper limit); Patients are currently participating in other clinical studies.